Since plasma DPP-4 activity is increased in patients with NAFLD [20] and patients who have type 2 diabetes with elevated liver enzymes [21], treatment with DPP-4 inhibitors may prevent the development of NASH. This evidence concerns the gene DPP4 and metabolic dysfunction-associated steatohepatitis.